Pacira Biosciences Inc represents a commitment to improving patient outcomes and transforming the surgical experience. Their corporate philosophy is centered around finding innovative solutions for postsurgical pain management and reducing opioid use. With a focus on responsible drug development, Pacira prioritizes patient safety, clinical evidence, and collaboration with healthcare professionals. The company strives to provide patients with non-opioid alternatives for pain control, aiming to enhance recovery and minimize the risk of opioid-related complications. Pacira Biosciences Inc emphasizes ethical practices and dedicated research to address unmet medical needs in surgical care.

Pacira Biosciences Inc is primarily present in various countries and regions worldwide. The company has established its presence in the United States, enabling it to cater to the North American market effectively. Additionally, Pacira Biosciences Inc has expanded its reach globally, with a strong presence in Europe, Asia, and other international regions. By strategically establishing its presence in multiple countries and regions, Pacira Biosciences Inc aims to provide its innovative healthcare solutions and products to a diverse range of patients and healthcare providers across the globe.

Pacira Biosciences Inc, a renowned pharmaceutical company, has achieved several significant milestones. Notably, the company successfully developed and commercialized Exparel, a cutting-edge non-opioid pain management medication widely used in surgical procedures. Pacira Biosciences Inc also made significant progress in expanding its product pipeline by successfully launching iovera, a minimally invasive treatment option for managing pain. Additionally, the company's continuous commitment to research and development has led to numerous innovative drug formulations and collaborations with global healthcare institutions. Through its steadfast dedication to improving patient outcomes, Pacira Biosciences Inc has cemented its position as a leading player in the pharmaceutical industry.

Pacira Biosciences Inc is a leading pharmaceutical company specializing in non-opioid pain management and regenerative health solutions. Established in 2006, the company is headquartered in Parsippany, New Jersey. Pacira Biosciences focuses on developing innovative therapies for acute pain management and surgical applications. With a dedication to improving patient outcomes and reducing opioid dependence, they have introduced groundbreaking products like EXPAREL®, a long-acting local analgesic. Pacira Biosciences has transformed pain management practices across various surgical specialties, providing patients with effective alternatives to opioids. The company's commitment to research, development, and pioneering advancements makes Pacira Biosciences Inc a trusted name in the healthcare industry.

The main competitors of Pacira Biosciences Inc in the market include Johnson & Johnson, Pfizer Inc, and Teva Pharmaceutical Industries Ltd. These companies operate in the pharmaceutical industry and offer similar products and services. Pacira Biosciences Inc faces competition in its primary focus area of developing and commercializing innovative pharmaceutical products for post-surgical pain management. Competitors like Johnson & Johnson, Pfizer Inc, and Teva Pharmaceutical Industries Ltd constantly strive to capture market share by introducing new products and technologies. However, Pacira Biosciences Inc has successfully positioned itself as a competitive player in the market through its strong product portfolio and focus on research and development efforts.

Pacira Biosciences Inc primarily operates in the pharmaceutical industry.

The business model of Pacira Biosciences Inc is focused on developing and commercializing innovative pharmaceutical products for use in hospitals and ambulatory surgery centers. The company specializes in creating and delivering non-opioid pain management therapies. Pacira Biosciences Inc's flagship product, EXPAREL®, is a long-acting local analgesic that provides extended pain relief after surgery. With a strong emphasis on research and development, Pacira Biosciences Inc aims to improve patient outcomes and reduce opioid consumption by providing alternative pain management solutions. This commitment to innovation and patient care drives the company's success in the healthcare industry.

Az KGV a Pacira Biosciences esetében jelenleg nem számítható ki.

A Pacira Biosciences számára az aktuális KUV nem számítható ki.

Az AlleAktien Minőségi Score Pacira Biosciences esetében 4/10.

A Pacira Biosciences esetében jelenleg nem számítható ki az árbevétel.

A nyereséget jelenleg nem lehet kiszámítani a Pacira Biosciences számára.

Pacira Biosciences Inc is a global pharmaceutical company specializing in the development, manufacturing, and marketing of innovative pain relief medications. The company was founded in 1999 and is headquartered in Parsippany, New Jersey, USA. It is listed on the NASDAQ stock exchange and employs over 1,300 people worldwide. The company's business model is based on the research and development of medications focused on pain treatment. Pacira Biosciences focuses on developing medications using its proprietary liposome technology, which helps to effectively and prolong the action of active substances in the body, thereby improving pain relief. Pacira Biosciences Inc's products mainly include Exparel (Bupivacaine liposome injectable suspension), a long-acting pain medication used for postoperative pain management. Exparel is used in orthopedics, gynecology, plastic surgery, general surgery, and other areas where pain relief is needed during the recovery phase after surgery. In addition to Exparel, Pacira Biosciences also has a pipeline of development projects for new medications, including DepoCyt (Cytarabine liposome injection), a medication for certain types of cancer. The company is divided into three business segments: Products, Research and Development, and Corporate. The Products segment is responsible for marketing and sales of Exparel in the US and Europe. The Research and Development segment is responsible for the development of new medications and pain therapy technologies. The Corporate segment coordinates general operational matters, finances, human resources, legal and compliance issues, as well as marketing and communication activities for the company. Overall, Pacira Biosciences Inc's business model focuses on developing and marketing innovative and effective pain medications based on its liposome technology. It primarily addresses the needs of patients and doctors for improved pain relief in postoperative pain management.

A(z) Pacira Biosciences évente alkalommal oszt ki 0 USD összegű osztalékot.

A Pacira Biosciences esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Pacira Biosciences ISIN kódja: US6951271005.

A Pacira Biosciences WKN-je A1H68T.

Az Pacira Biosciences tőzsdei rövidítése PCRX.

Az elmúlt 12 hónapban a(z) Pacira Biosciences osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) Pacira Biosciences várhatóan 0 USD összegű osztalékot fog fizetni.

A(z) Pacira Biosciences jelenlegi osztalékhozama .

A(z) Pacira Biosciences negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A Pacira Biosciences az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 USD összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) Pacira Biosciences a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Pacira Biosciences által 2024. 09. 18.-án/én fizetett 0 USD összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 09. 18.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2024. 09. 18. időpontban történt.

2023 évben a Pacira Biosciences 0 USD összegű osztalékot fizetett ki.

Az Pacira Biosciences osztalékait USD fizeti ki.